{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:23:44Z","timestamp":1790835824020,"version":"4.1.0"},"reference-count":325,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Association for Cancer Research (AIRC)","award":["20353"],"award-info":[{"award-number":["20353"]}]},{"name":"Italian Association for Cancer Research (AIRC)","award":["Frailcures"],"award-info":[{"award-number":["Frailcures"]}]},{"name":"Progetti Dimesist","award":["20353"],"award-info":[{"award-number":["20353"]}]},{"name":"Progetti Dimesist","award":["Frailcures"],"award-info":[{"award-number":["Frailcures"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) induce cytotoxic effects as single agents in tumors characterized by defective repair of DNA double-strand breaks deriving from BRCA1\/2 mutations or other abnormalities in genes associated with homologous recombination. Preclinical studies have shown that PARPi-induced DNA damage may affect the tumor immune microenvironment and immune-mediated anti-tumor response through several mechanisms. In particular, increased DNA damage has been shown to induce the activation of type I interferon pathway and up-regulation of PD-L1 expression in cancer cells, which can both enhance sensitivity to Immune Checkpoint Inhibitors (ICIs). Despite the recent approval of ICIs for a number of advanced cancer types based on their ability to reinvigorate T-cell-mediated antitumor immune responses, a consistent percentage of treated patients fail to respond, strongly encouraging the identification of combination therapies to overcome resistance. In the present review, we analyzed both established and unexplored mechanisms that may be elicited by PARPi, supporting immune reactivation and their potential synergism with currently used ICIs. This analysis may indicate novel and possibly patient-specific immune features that might represent new pharmacological targets of PARPi, potentially leading to the identification of predictive biomarkers of response to their combination with ICIs.<\/jats:p>","DOI":"10.3390\/cancers14225633","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:27:44Z","timestamp":1668655664000},"page":"5633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints"],"prefix":"10.3390","volume":"14","author":[{"given":"Ornella","family":"Franzese","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-768X","authenticated-orcid":false,"given":"Grazia","family":"Graziani","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/ncomms3240","article-title":"A systematic analysis of the PARP protein family identifies new functions critical for cell physiology","volume":"4","author":"Vyas","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1038\/ncomms5426","article-title":"Family-wide analysis of poly (ADP-ribose) polymerase activity","volume":"5","author":"Vyas","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1128\/MCB.02248-06","article-title":"Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydro-lase","volume":"27","author":"Fisher","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: Reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1083\/jcb.200806068","article-title":"PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA","volume":"183","author":"Sugimura","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1083\/jcb.201012132","article-title":"PARP regulates nonhomologous end joining through retention of Ku at double-strand breaks","volume":"194","author":"Couto","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_8","first-page":"228","article-title":"The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells","volume":"3","author":"Patel","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","article-title":"The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication","volume":"71","author":"Hanzlikova","year":"2018","journal-title":"Mol. Cell."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and its associated nucleases in DNA damage response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA Repair: Additional Functions of PARP-1 in Cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1093\/nar\/gku474","article-title":"PARP-2 and PARP-3 are selectively activated by 5\u2019 phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1","volume":"42","author":"Langelier","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_14","first-page":"1","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2","author":"Heeke","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4161\/cc.4.9.2031","article-title":"Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy","volume":"4","author":"Helleday","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/2159-8290.CD-13-0891","article-title":"PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair","volume":"4","author":"Hu","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art","volume":"84","author":"Schreiber","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risk due to in-herited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13053-015-0038-x","article-title":"The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers","volume":"13","author":"Cavanagh","year":"2015","journal-title":"Her. Cancer Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103033","DOI":"10.1016\/j.ebiom.2020.103033","article-title":"Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes","volume":"60","author":"Mizukami","year":"2020","journal-title":"EBioMed"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e46263","DOI":"10.15252\/embr.201846263","article-title":"Mechanisms for stalled replication fork stabiliza-tion: New targets for synthetic lethality strategies in cancer treatments","volume":"19","author":"Liao","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Faraoni, I., and Graziani, G. (2018). Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 10.","DOI":"10.3390\/cancers10120487"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"785102","DOI":"10.3389\/fonc.2021.785102","article-title":"Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"44657","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping Poly(ADP-Ribose) Polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R D"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_37","first-page":"877","article-title":"European regulators approve first PARP inhibitor","volume":"13","author":"Mullard","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","first-page":"CD011395","article-title":"PARP (Poly ADP-Ribose Polymer-ase) inhibitors for locally advanced or metastatic breast cancer","volume":"4","author":"Taylor","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","first-page":"CD007929","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_43","first-page":"103","article-title":"Immune Checkpoint Inhibitors in the Treatment of Cancer","volume":"17","author":"Zam","year":"2022","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-018-0120-y","article-title":"The role of neoantigen in immune checkpoint blockade therapy","volume":"7","author":"Yi","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"672356","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: A New Breakthrough in Tumor Immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Martinez, A., Delord, J.P., Ayyoub, M., and Devaud, C. (2020). Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071761"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Martin","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13046-016-0456-2","article-title":"Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic","volume":"35","author":"Cerrato","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Keung, M., Wu, Y., and Vadgama, J.V. (2019). PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040435"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Germani, A., Petrucci, S., De Marchis, L., Libi, F., Savio, C., Amanti, C., Bonifacino, A., Campanella, B., Capalbo, C., and Lombardi, A. (2020). Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast\/Ovarian and Pancreatic Cancers. J. Clin. Med., 9.","DOI":"10.3390\/jcm9093003"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dalmasso, B., Puccini, A., Catalano, F., Borea, R., Iaia, M.L., Bruno, W., Fornarini, G., Sciallero, S., Rebuzzi, S.E., and Ghiorzo, P. (2022). Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094709"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/gm175","article-title":"Environmental exposures and mutational patterns of cancer genomes","volume":"2","author":"Pfeifer","year":"2010","journal-title":"Genome Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/modpathol.2014.143","article-title":"Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations","volume":"28","author":"Hussein","year":"2015","journal-title":"Modern Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-14-1397","article-title":"The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy","volume":"5","author":"Xiao","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.adro.2018.08.017","article-title":"The DNA damage response in immunotherapy and radiation","volume":"3","author":"Samstein","year":"2018","journal-title":"Adv. Rad. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","volume":"7","author":"Vidotto","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"689076","DOI":"10.3389\/fimmu.2021.689076","article-title":"Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer","volume":"12","author":"Zou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/eji.201343781","article-title":"The DNA damage response induces antigen presenting cell-like functions in fibroblasts","volume":"44","author":"Tang","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2020.01.030","article-title":"Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models","volume":"108","author":"Seyedin","year":"2020","journal-title":"Int. Ernational J. Rad. Oncol. Biol. Phys."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: More haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"ra20","DOI":"10.1126\/scisignal.2002521","article-title":"STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway","volume":"5","author":"Tanaka","year":"2012","journal-title":"Sci. Signal"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.immuni.2016.04.010","article-title":"The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells","volume":"44","author":"Ho","year":"2016","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: Infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s42003-021-02983-5","article-title":"SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-\u03baB","volume":"5","author":"Neufeldt","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Sign. Trans. Target. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1128\/JVI.00037-14","article-title":"Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-\u03baB activation through TBK1","volume":"88","author":"Abe","year":"2014","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent Innate Immune Signaling By S-phase-Specific DNA Damage in Breast Cancer","volume":"109","author":"Parkes","year":"2016","journal-title":"J. Nat. Cancer Inst."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1758835920944116","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: Scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Y\u00e9lamos, J., Moreno-Lama, L., Jimeno, J., and Ali, S.O. (2020). Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies. Cancers, 12.","DOI":"10.3390\/cancers12020392"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Ishii","year":"2015","journal-title":"J. Thor. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/esmoopen-2015-000022","article-title":"Immune checkpoint blockade in small cell lung cancer: Is there a light at the end of the tunnel?","volume":"1","author":"Paglialunga","year":"2016","journal-title":"ESMO"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2083755","DOI":"10.1080\/2162402X.2022.2083755","article-title":"PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors","volume":"11","author":"Staniszewska","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fimmu.2018.00711","article-title":"Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies","volume":"9","author":"Iurescia","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1084\/jem.189.5.803","article-title":"T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice","volume":"189","author":"Qin","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e12441","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNF\u03b1 and IFN\u03b3: A comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Saenz, L., Lozano, J.J., Valdor, R., Baroja-Mazo, A., Ramirez, P., Parrilla, P., Aparicio, P., Sumoy, L., and Y\u00e9lamos, J. (2008). Transcriptional regulation by poly(ADP-ribose) polymerase-1 during T cell activation. BMC Genom., 9.","DOI":"10.1186\/1471-2164-9-171"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1398-9995.2011.02549.x","article-title":"PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model","volume":"66","author":"Datta","year":"2011","journal-title":"Allergy"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-015-0583-0","article-title":"PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function","volume":"13","author":"Ghonim","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cr.7310002","article-title":"GATA-3 promotes Th2 responses through three different mechanisms: Induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors","volume":"16","author":"Zhu","year":"2005","journal-title":"Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zong, W., Gong, Y., Sun, W., Li, T., and Wang, Z.Q. (2022). PARP1: Liaison of Chromatin Remodeling and Transcription. Cancers, 14.","DOI":"10.3390\/cancers14174162"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.immunol.23.021704.115821","article-title":"Regulation of Th2 differentiation and Il4 locus accessibility","volume":"24","author":"Ansel","year":"2006","journal-title":"Ann. Rev. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhang, P., Maruyama, T., Konkel, J.E., Abbatiello, B., Zamarron, B., Wang, Z.Q., and Chen, W. (2013). PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071590"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"28675","DOI":"10.1074\/jbc.M115.661611","article-title":"Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells","volume":"290","author":"Luo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4049\/jimmunol.0901568","article-title":"Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency","volume":"184","author":"Nasta","year":"2010","journal-title":"J. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"683419","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2100225118","DOI":"10.1073\/pnas.2100225118","article-title":"TBK1 recruitment to STING activates both IRF3 and NF-\u03baB that mediate immune defense against tumors and viral infections","volume":"118","author":"Yum","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expres-sion and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_119","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","article-title":"The renaissance of GSK3","volume":"2","author":"Cohen","year":"2001","journal-title":"Nat. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1038\/sj.emboj.7601301","article-title":"PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes","volume":"25","author":"Monreal","year":"2006","journal-title":"EMBO J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Lan, T., Chen, L., and Wei, X. (2021). Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells, 10.","DOI":"10.3390\/cells10010100"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"292376","DOI":"10.1155\/2014\/292376","article-title":"The inflammatory chemokine CCL5 and cancer progression","volume":"2014","author":"Aldinucci","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2174\/138955751513150923094709","article-title":"Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer","volume":"15","author":"Khalid","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Aldinucci, D., Borghese, C., and Casagrande, N. (2020). The CCL5\/CCR5 Axis in Cancer Progression. Cancers, 12.","DOI":"10.3390\/cancers12071765"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41698-021-00189-w","article-title":"PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bcp.2008.11.014","article-title":"CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways","volume":"77","author":"Huang","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3858\/emm.2008.40.5.514","article-title":"LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression","volume":"40","author":"Kim","year":"2008","journal-title":"Exp. Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cyto.2013.06.313","article-title":"CCR1\/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2\/9 and by activating ERK and Rac signaling","volume":"64","author":"Kato","year":"2013","journal-title":"Cytokine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/ijbs.58784","article-title":"Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation","volume":"18","author":"Li","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1242\/jcs.133108","article-title":"ERM proteins in cancer progression","volume":"127","author":"Clucas","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0090-8258(03)00262-2","article-title":"Ezrin immunoreactivity in relation to survival in serous ovari-an carcinoma patients","volume":"90","author":"Moilanen","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Horwitz, V., Davidson, B., Stern, D., Trop\u00e9, C.G., Tavor Re\u2019em, T., and Reich, R. (2016). Ezrin Is Associated with Disease Progression in Ovarian Carcinoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162502"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1084\/jem.173.4.1017","article-title":"DNA sequence analysis of NKG2, a family of related cDNA clones en-coding type II integral membrane proteins on human natural killer cells","volume":"173","author":"Houchins","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1074-7613(02)00333-3","article-title":"The role of the NKG2D immuno-receptor in immune cell activation and natural killing","volume":"17","author":"Jamieson","year":"2002","journal-title":"Immunity"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","article-title":"Leveraging NKG2D Ligands in Immuno-Oncology","volume":"12","author":"Fuertes","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/77793","article-title":"Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages","volume":"1","author":"Diefenbach","year":"2000","journal-title":"Nat. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.174.8.4480","article-title":"NKG2D is a costimulatory receptor for human naive CD8+ T cells","volume":"174","author":"Maasho","year":"2005","journal-title":"J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.175.5.2825","article-title":"Costimulation through NKG2D enhances murine CD8+ CTL function: Similarities and differences between NKG2D and CD28 costimulation","volume":"175","author":"Markiewicz","year":"2005","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/cmi.2017.161","article-title":"Functions of NKG2D in CD8+ T cells: An opportunity for immunotherapy","volume":"15","author":"Prajapati","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Rajasekaran, K., Xiong, V., Fong, L., Gorski, J., and Malarkannan, S. (2010). Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012635"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4049\/jimmunol.145.1.344","article-title":"The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity","volume":"145","author":"Lee","year":"1990","journal-title":"J. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.4049\/jimmunol.178.12.7710","article-title":"The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation","volume":"178","author":"Plunkett","year":"2007","journal-title":"J. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and Its Ligands: \u201cOne for All, All for One\u201d","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1074-7613(00)80222-8","article-title":"Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice","volume":"12","author":"Cerwenka","year":"2000","journal-title":"Immunity"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(01)00187-X","article-title":"Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60","volume":"15","author":"Cerwenka","year":"2001","journal-title":"Immunity"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Champsaur","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/eji.200940278","article-title":"NKG2D performs two functions in invariant NKT cells: Direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d","volume":"41","author":"Kuylenstierna","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2004-07-2585","article-title":"Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelo-monocytic cells but at low levels in acute myeloid leukemias","volume":"105","author":"Nowbakht","year":"2005","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: Implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des.Dev. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"TPS3102","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3102","article-title":"A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML\/MDS and multiple myeloma","volume":"34","author":"Nikiforow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother. Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2015.162","article-title":"Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy","volume":"23","author":"Lynn","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_163","first-page":"2649","article-title":"AMXI-5001, a novel dual parp1\/2 and microtubule polymerization inhibitor for the treatment of human cancers","volume":"10","author":"Peto","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Molfetta, R., Zitti, B., Lecce, M., Milito, N.D., Stabile, H., Fionda, C., Cippitelli, M., Gismondi, A., Santoni, A., and Paolini, R. (2020). CD155: A Multi-Functional Molecule in Tumor Progression. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030922"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-04-2682","article-title":"Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction","volume":"64","author":"Castriconi","year":"2004","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molimm.2015.11.009","article-title":"Expression of DNAM-1 (CD226) on inflammatory monocytes","volume":"69","author":"Vo","year":"2016","journal-title":"Mol. Immunol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fcell.2020.00564","article-title":"CD226: An Emerging Role in Immunologic Diseases","volume":"8","author":"Huang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.molimm.2008.06.016","article-title":"NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways","volume":"45","author":"Verhoeven","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"Meade","year":"2007","journal-title":"Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e1338994","DOI":"10.1080\/2162402X.2017.1338994","article-title":"Cd226-\/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo","volume":"6","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"902","DOI":"10.4049\/jimmunol.0903225","article-title":"DNAM-1\/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases","volume":"184","author":"Chan","year":"2010","journal-title":"J. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imcb.12205","article-title":"The Immune Checkpoint CD96 Defines a Distinct Lymphocyte Phenotype and is Highly Expressed on Tumor-Infiltrating T Cells","volume":"97","author":"Lepletier","year":"2019","journal-title":"Immunol. Cell. Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.4049\/jimmunol.1300945","article-title":"The CD226\/CD155 interaction regulates the proinflammatory (Th1\/Th17)\/anti-inflammatory (Th2) balance in humans","volume":"191","author":"Lozano","year":"2013","journal-title":"J. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.4049\/jimmunol.1401972","article-title":"Coordinated expression of DNAM-1 and LFA-1 in educated NK cells","volume":"194","author":"Enqvist","year":"2015","journal-title":"J. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"15627","DOI":"10.1038\/ncomms15627","article-title":"Expression of CD226 is associated to but not required for NK cell education","volume":"8","author":"Wagner","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.celrep.2015.03.006","article-title":"DNAM-1 expression marks an alternative program of NK cell maturation","volume":"11","author":"Martinet","year":"2015","journal-title":"Cell Rep."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1084\/jem.20030958","article-title":"CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation","volume":"198","author":"Shibuya","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1074-7613(00)80136-3","article-title":"Physical and functional association of LFA-1 with DNAM-1 adhesion molecule","volume":"11","author":"Shibuya","year":"1999","journal-title":"Immunity"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1084\/jem.20081611","article-title":"Accelerated tumor growth in mice deficient in DNAM-1 receptor","volume":"205","author":"Kai","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1084\/jem.20150792","article-title":"DNAM-1 controls NK cell activation via an ITT-like motif","volume":"212","author":"Zhang","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Yeo, J., Ko, M., Lee, D.H., Park, Y., and Jin, H.S. (2021). TIGIT\/CD226 Axis Regulates Anti-Tumor Immunity. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030200"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-Dose Bortezomib Increases the Expression of NKG2D and DNAM-1 Ligands and Enhances Induced NK and Gammadelta T Cell-Mediated Lysis in Multiple Myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","article-title":"The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer","volume":"39","author":"Lambert","year":"2021","journal-title":"Cancer Cell."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e003134","DOI":"10.1136\/jitc-2021-003134","article-title":"TIGIT\/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment","volume":"9","author":"Kawashima","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"105472","DOI":"10.1016\/j.oraloncology.2021.105472","article-title":"TIGIT\/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells","volume":"121","author":"Mao","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/JID.2015.404","article-title":"Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase","volume":"136","author":"Inozume","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000500902","article-title":"On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment","volume":"64","author":"Tundo","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jid.2015.10.048","article-title":"TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention","volume":"136","author":"Mahnke","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00262-016-1799-4","article-title":"Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155","volume":"65","author":"Zhang","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e004711","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: Advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/2326-6066.CIR-19-0877","article-title":"CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy","volume":"8","author":"Jin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT, a novel immune checkpoint in human cancers","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e2021309118","DOI":"10.1073\/pnas.2021309118","article-title":"DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions","volume":"118","author":"Sato","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Diff."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"681320","DOI":"10.3389\/fphar.2021.681320","article-title":"Clinical Insights into Novel Immune Checkpoint Inhibitors","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1038\/s41467-020-18256-4","article-title":"Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection","volume":"11","author":"Sandu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-12-385526-8.00010-2","article-title":"Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity","volume":"61","author":"Deaglio","year":"2011","journal-title":"Adv. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.febslet.2015.07.027","article-title":"CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression","volume":"589","author":"Bono","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD (+) Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell. Metab."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The Multi-faceted Ecto enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/08820139.2019.1566356","article-title":"Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer","volume":"48","author":"Zhang","year":"2019","journal-title":"Immunol. Investig."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbrc.2006.05.042","article-title":"Regulation of intracellular levels of NAD: A novel role for CD38","volume":"345","author":"Aksoy","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus","volume":"22","author":"Menzies","year":"2015","journal-title":"Cell Metab."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Kar, A., Mehrotra, S., and Chatterjee, S. (2020). CD38: T Cell Immuno-Metabolic Modulator. Cells, 9.","DOI":"10.3390\/cells9071716"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbrc.2006.08.066","article-title":"Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38","volume":"349","author":"Aksoy","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1101\/gad.193193.112","article-title":"CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells","volume":"26","author":"Wright","year":"2012","journal-title":"Genes Develop."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.celrep.2014.08.036","article-title":"ARTD1\/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion","volume":"8","author":"Fouquerel","year":"2014","journal-title":"Cell Rep."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1091\/mbc.E18-10-0650","article-title":"NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival","volume":"30","author":"Murata","year":"2019","journal-title":"Mol. Biol. Cell."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the Complex Interplay Between T Cell Metabolism and Function","volume":"26","author":"Geltink","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"658263","DOI":"10.3389\/fimmu.2021.658263","article-title":"The Key Role of NAD+ in Anti-Tumor Immune Response: An Update","volume":"12","author":"Morandi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.7150\/ijbs.49735","article-title":"The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response","volume":"16","author":"Jiang","year":"2020","journal-title":"Int. J. Biol Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"104347","DOI":"10.1016\/j.isci.2022.104347","article-title":"Functional assessment of the cell-autonomous role of NADase CD38 in regulating CD8+ T cell exhaustion","volume":"25","author":"Ma","year":"2022","journal-title":"iScience"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/bi201509f","article-title":"Catalysis-based inhibitors of the calcium signaling function of CD38","volume":"51","author":"Kwong","year":"2012","journal-title":"Biochemistry"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"13243","DOI":"10.1074\/jbc.M117.789347","article-title":"Synthesis of the Ca(2+)-mobilizing messengers NAADP and cADPR by intracellular CD38 enzyme in the mouse heart: Role in beta-adrenoceptor signaling","volume":"292","author":"Lin","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0968-0004(92)90337-9","article-title":"Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38","volume":"17","author":"States","year":"1992","journal-title":"Trends Biochem. Sci."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s00262-021-02949-w","article-title":"CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer","volume":"70","author":"Sato","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"109516","DOI":"10.1016\/j.celrep.2021.109516","article-title":"NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: Key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0092-8674(02)00699-2","article-title":"NFAT signaling: Choreographing the social lives of cells","volume":"109","author":"Crabtree","year":"2002","journal-title":"Cell"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.onc.1204386","article-title":"Partners in transcription: NFAT and AP-1","volume":"20","author":"Macian","year":"2001","journal-title":"Oncogene"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.8235597","article-title":"Isolation of the cyclosporin-sensitive T cell transcription factor NFATp","volume":"262","author":"McCaffrey","year":"1993","journal-title":"Science"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1084\/jem.187.12.2031","article-title":"Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300\/CREB-binding protein (CBP)","volume":"187","author":"Rao","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1097-2765(02)00701-3","article-title":"NFATc2-mediated repression of cyclin-dependent kinase 4 expression","volume":"10","author":"Baksh","year":"2002","journal-title":"Mol. Cell."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.1128\/MCB.25.22.9936-9948.2005","article-title":"The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment","volume":"25","author":"Dai","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.molimm.2007.10.044","article-title":"Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells","volume":"45","author":"Valdor","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1128\/MCB.01746-07","article-title":"Regulation of transcription factor NFAT by ADP-ribosylation","volume":"28","author":"Olabisi","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: A transcription factor comes of age","volume":"10","author":"Rao","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2019-0846","article-title":"Emerging Therapeutic Implications of STK11 Mutation: Case Series","volume":"25","author":"Laderian","year":"2020","journal-title":"Oncologist"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"73389","DOI":"10.18632\/oncotarget.12334","article-title":"LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-18-1286","article-title":"Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers","volume":"9","author":"Byers","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jtho.2021.01.298","article-title":"PARP1 Inhibitors Enhanced IFN\u03b3-Induced PD-L1 Expression in LKB1-Mutant Lung Cancer","volume":"16","author":"Bai","year":"2021","journal-title":"J. Thor. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2013-05-503250","article-title":"PARP-1 regulates expression of TGF-\u03b2 receptors in T cells","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: Guardian of T cell function","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/ni.1677","article-title":"IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells","volume":"9","author":"Dardalhon","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/0008-5472.CAN-15-1545","article-title":"TGF\u03b2 Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment","volume":"76","author":"Boutet","year":"2016","journal-title":"Cancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","article-title":"Tissue-resident memory T cells","volume":"41","author":"Schenkel","year":"2014","journal-title":"Immunity"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/dvdy.21685","article-title":"Integrin-linked kinase regulates E-cadherin expression through PARP-1","volume":"237","author":"McPhee","year":"2008","journal-title":"Dev. Dyn."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1242\/jcs.114.6.1125","article-title":"Overexpression ofthe integrin-linked kinase mesenchymally transforms mammary epithelial cells","volume":"114","author":"Somasiri","year":"2001","journal-title":"J. Cell. Sci."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","article-title":"Resident memory T cells, critical components in tumor immunology","volume":"6","author":"Blanc","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0959-8049(02)00633-0","article-title":"CD103+ intraepithelial lymphocytes-a unique population in microsatellite unstable sporadic colorectal cancer","volume":"2003","author":"Quinn","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.juro.2015.02.2941","article-title":"CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder","volume":"194","author":"Wang","year":"2015","journal-title":"J. Urol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3389\/fimmu.2018.01904","article-title":"The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin","volume":"9","author":"Corgnac","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1182\/blood-2009-06-228353","article-title":"Immunoregulatory functions of KLRG1 cadherin interactions are dependent on forward and reverse signaling","volume":"114","author":"Banh","year":"2009","journal-title":"Blood"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20071641","article-title":"Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates","volume":"205","author":"Sarkar","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ni.3410","article-title":"A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet","volume":"17","author":"Xin","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3031","article-title":"Molecular regulation of effector and memory T cell differentiation","volume":"15","author":"Chang","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-immunol-032414-112014","article-title":"T Cell Fate at the Single-Cell Level","volume":"34","author":"Buchholz","year":"2016","journal-title":"Ann. Rev. Immunol."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Yang, X., Zheng, Y., Han, Z., and Zhang, X. (2021). Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy. BMC Cancer, 29.","DOI":"10.21203\/rs.3.rs-59360\/v1"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bcp.2018.10.005","article-title":"PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome","volume":"162","author":"Tapodi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e47978","DOI":"10.1371\/journal.pone.0047978","article-title":"PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent","volume":"7","author":"Ethier","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.celrep.2017.01.009","article-title":"Regulation of Serine-Threonine Kinase Akt Activation by NAD(+)-Dependent Deacetylase SIRT7","volume":"18","author":"Yu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_263","first-page":"1677","article-title":"Reduction of SIRT1 blunts the protective effects of ischemic post-conditioning in diabetic mice by impairing the Akt signaling pathway","volume":"1865","author":"Ding","year":"2019","journal-title":"Biochem. Biophys. Acta"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14336\/AD.2021.0729","article-title":"Mammalian AKT, the Emerging Roles on Mitochondrial Function in Diseases","volume":"13","author":"Xie","year":"2022","journal-title":"Aging Dis."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR Pathway Causes Drug Resistance in Breast Cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharm."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2011.01.012","article-title":"Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism","volume":"34","author":"Macintyre","year":"2011","journal-title":"Immunity"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fimmu.2013.00020","article-title":"Role of PI3K\/Akt signaling in memory CD8 T cell differentiation","volume":"4","author":"Kim","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1182\/blood-2009-01-199588","article-title":"KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8C T cells","volume":"113","author":"Henson","year":"2009","journal-title":"Blood"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"e1294","DOI":"10.1038\/cddis.2014.259","article-title":"Defect in HSP90 expression in highly differentiated human CD8(+) T lymphocytes","volume":"5","author":"Franzese","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-065X.2003.00008.x","article-title":"The PI-3 kinase\/Akt pathway and T cell activation: Pleiotropic pathways downstream of PIP3","volume":"192","author":"Kane","year":"2003","journal-title":"Immunol. Rev."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nri2888","article-title":"Metabolism, migration and memory in cytotoxic T cells","volume":"11","author":"Finlay","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"e1114203","DOI":"10.1080\/2162402X.2015.1114203","article-title":"Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS","volume":"5","author":"Franzese","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-04-2633","article-title":"Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence","volume":"65","author":"Hirose","year":"2005","journal-title":"Cancer Res."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/mol.107.044743","article-title":"AKT is activated in an n response to temozolomide and confers protection against drug-induced cell growth inhibition","volume":"74","author":"Caporali","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","article-title":"Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co- receptor PD-1 to enhance CD8(+) cytolytic T cell responses","volume":"44","author":"Taylor","year":"2016","journal-title":"Immunity"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","article-title":"Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Cancer Res."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Lorusso, D., Maiorano, M., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., and Maiello, E. (2022). The In-terplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073871"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"165.35","DOI":"10.4049\/jimmunol.204.Supp.165.35","article-title":"CD28 and glycogen synthase kinase-3 (GSK-3) inhibitor combination therapy generates tumor infiltrating T-cells (TILs) with a reversal of markers for T-cell exhaustion","volume":"204","author":"Kazanova","year":"2020","journal-title":"J. Immunol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"e001643","DOI":"10.1136\/jitc-2020-001643","article-title":"Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer","volume":"9","author":"Ghonim","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"816642","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination with Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women\u2019s Cancers: A Dose-Escalation, phase I Study","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2018.04.555","article-title":"An Open- Label, phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Germline BRCA-Mutated (gBRCAm) Platinum-Sensitive Relapsed (PSR) Ovarian Cancer (OC)","volume":"149","author":"Drew","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.017","article-title":"Phase II Study of Olaparib (O) and Durvalumab (D) (MEDIOLA): Updated Results in Patients (Pts) With Germline BRCA-Mutated (gBRCAm), Metastatic Breast Cancer (MBC)","volume":"30","author":"Domchek","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in Combination with Tislelizumab in Patients with Advanced Solid Tumours: Results from the Dose-Escalation Stage of a Multicentre, Open-Label, phase 1a\/B Trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-of-Concept Phase II Study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"TPS9","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS9","article-title":"JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer","volume":"37","author":"Eskander","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a phase II Study","volume":"14","author":"Thomas","year":"2019","journal-title":"J. Thor. Oncol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"TPS2660","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2660","article-title":"JAVELIN BRCA\/ATM: A phase 2 trial of avelumab (anti\u2013PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1\/2 or ATM defect","volume":"37","author":"Hyman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"TPS5600","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5600","article-title":"ENGOT-OV44\/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3\/4 non-mucinous epithelial ovarian cancer (OC)","volume":"37","author":"Moore","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_294","first-page":"ix89","article-title":"ENGOT-ov43\/KEYLYNK-001: A Phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA\u2019-nonmutated advanced epithelial ovarian cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","article-title":"ATHENA (GOG-3020\/ENGOT-ov45): A randomized, Phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","volume":"31","author":"Monk","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"TPS5598","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5598","article-title":"DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients","volume":"37","author":"Harter","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ijgc-2021-002593","article-title":"Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician\u2019s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)","volume":"31","author":"Musacchio","year":"2021","journal-title":"Int. J. Gyn. Cancer"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ijgc-2020-001633","article-title":"A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41\/GEICO 69-O\/ANITA Trial","volume":"31","author":"Colombo","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_299","first-page":"15","article-title":"ROCSAN trial (GINECO-EN203b\/ENGOT-EN8): A multicenter randomized phase 2\/3 evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial\/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy","volume":"39","author":"Leary","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_300","first-page":"15","article-title":"DUO-E\/GOG-3041\/ENGOT-EN10: A randomized Phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC)","volume":"38","author":"Moore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Singh, D.D., Parveen, A., and Yadav, D.K. (2021). Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111512"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"TPS596","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS596","article-title":"KEYLYNK-009: A Phase II\/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","volume":"38","author":"Rugo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbrc.2019.11.050","article-title":"Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors","volume":"522","author":"Ji","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.annonc.2021.08.1961","article-title":"First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced\/ metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study","volume":"32","author":"Ramalingam","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"TPS9632","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9632","article-title":"Randomized Phase III study of first line pembrolizumab plus pemetrexed\/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006","volume":"38","author":"Gray","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8580","article-title":"Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012","volume":"39","author":"Jabbour","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.annonc.2020.08.1732","article-title":"Randomized, placebo-controlled Phase III study of 1L pembrolizumab (Pembro) plus carboplatin\/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008","volume":"31","author":"Gray","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2020.38.15_suppl.5544","article-title":"Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010","volume":"38","author":"Yu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2018.36.5_suppl.48","article-title":"A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors","volume":"36","author":"Friedlander","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"e17052","DOI":"10.1200\/JCO.2017.35.15_suppl.e17052","article-title":"Phase I Study Combining Olaparib and Tremelimumab for the Treatment of Women With BRCA-Deficient Recurrent Ovarian Cancer","volume":"35","author":"Adams","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Skelding, K.A., and Lincz, L.F. (2021). PARP Inhibitors and Haematological Malignancies-Friend or Foe?. Cancers, 13.","DOI":"10.3390\/cancers13215328"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., and Laird, P.W. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","article-title":"A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia","volume":"23","author":"Gojo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","article-title":"A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia","volume":"23","author":"Pratz","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2011-11-391722","article-title":"Monocytic AML cells inactivate antileukemic lymphocytes: Role of NADPH oxidase\/gp91(phox) expression and the PARP-1\/PAR pathway of apoptosis","volume":"119","author":"Aurelius","year":"2012","journal-title":"Blood"},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Cai, L., Xu, X., and Chen, W. (2022). The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081647"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.7150\/thno.36281","article-title":"A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/jnci\/djr218","article-title":"Randomized phase II trials: A long-term investment with promising returns","volume":"103","author":"Sharma","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and Immune-Checkpoint Inhibitor Combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","article-title":"A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy","volume":"76","author":"Makvandi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"e146592","DOI":"10.1172\/jci.insight.146592","article-title":"In vivo visualization of PARP inhibitor pharmacodynamics","volume":"6","author":"McDonald","year":"2021","journal-title":"JCI Insight"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:19:44Z","timestamp":1760145584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":325,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14225633"],"URL":"https:\/\/doi.org\/10.3390\/cancers14225633","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}